[1]《恩格列净/二甲双胍复方制剂临床应用专家指导意见》编写组.恩格列净/二甲双胍复方制剂临床应用专家指导意见[J].国际内分泌代谢杂志,2022,42(05):451-456.[doi:10.3760/cma.j.cn121383-20220530-05068]
　Expert Group for Guidance of EMPA/MET FDC.Expert opinion on empagliflozin/metformin fixed-dose combination for treatment of type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2022,42(05):451-456.[doi:10.3760/cma.j.cn121383-20220530-05068]
点击复制

恩格列净/二甲双胍复方制剂临床应用专家指导意见()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年05期
页码:
451-456
栏目:
指南与共识
出版日期:
2022-09-20

文章信息/Info

Title:
Expert opinion on empagliflozin/metformin fixed-dose combination for treatment of type 2 diabetes
作者:
《恩格列净/二甲双胍复方制剂临床应用专家指导意见》编写组
Author(s):
Expert Group for Guidance of EMPA/MET FDC
Type 2 diabetes mellitus(T2DM)and its complications enforce heavy social and family medical economic burden, and there is great need to develop more effective novel drugs to improve clinical outcome. Metformin is the basic drug for treating T2DM. Besides potent hypoglycemic effect, it has additional benefits, and can be used in combination with various hypoglycemic drugs. In addition to its significant hypoglycemic effect, the new hypoglycemic drug empagliflozin can also reduce body weight, blood pressure and serum levels of uric acid, and has the validated protective effects on heart and kidney. Empagliflozin/metformin fixed-dose combination has definite curative effect, with advantages of reducing dosing frequency and improving patients' compliance. It provides a simple and effective option for clinic treatment.
关键词:
恩格列净;  二甲双胍;  动脉粥样硬化性心血管病;  慢性肾脏疾病;  心力衰竭
DOI:
10.3760/cma.j.cn121383-20220530-05068
摘要:
2型糖尿病及其并发症带来沉重的社会和家庭医疗经济负担,需要更为有效的新型治疗药物以改善其临床结局。二甲双胍是治疗2型糖尿病的基础用药,具有强效降糖以及降糖之外的多种益处,可与多种降糖药联用。新型降糖药物恩格列净除具有良好的降糖效果外,还能减轻体重、降低血压和血尿酸水平,具有明确的心血管和肾脏保护作用。恩格列净/二甲双胍复方制剂疗效确切,可以减少患者服药次数,提高依从性,为临床提供了一种简便有效的治疗选择。
Abstract:
Empagliflozin; Metformin; Atherosclerotic cardiovascular disease; Chronic kidney disease; Heart failure

参考文献/References:

[1] Ji L,Lu J,Weng J,et al.China type 2 diabetes treatment status survey of treatment pattern of oral drugs users[J].J Diabetes,2015,7(2):166-173.DOI:10.1111/1753-0407.12165.
[2] American Diabetes Association Professional Practice Committee,Draznin B,Aroda VR,Bakris G,et al.9.Pharmacologic approaches to glycemic treatment:Standards of Medical Care in Diabetes-2022[J].Diabetes Care,2022,45(Suppl 1):S125-S143.DOI:10.2337/dc22-S009.
[3] Liakos A,Karagiannis T,Athanasiadou E,et al.Efficacy and safety of empagliflozin for type 2 diabetes:a systematic review and meta-analysis[J].Diabetes Obes Metab,2014,16(10):984-993.DOI:10.1111/dom.12307.
[4] Salsali A,Kim G,Woerle HJ,et al.Cardiovascular safety of empagliflozin in patients with type 2 diabetes:a meta-analysis of data from randomized placebo-controlled trials[J]. Diabetes Obes Metab,2016,18(10):1034-1040.DOI:10.1111/dom.12734.
[5] Glossmann HH,Lutz OMD.Pharmacology of metformin-an update[J].Eur J Pharmacol,2019,865:172782.DOI:10.1016/j.ejphar.2019.172782.
[6] Grempler R,Thomas L,Eckhardt M,et al.Empagliflozin,a novel selective sodium glucose cotransporter-2(SGLT-2)inhibitor:characterisation and comparison with other SGLT-2 inhibitors[J].Diabetes Obes Metab,2012,14(1):83-90.DOI:10.1111/j.1463-1326.2011.01517.x.
[7] Filippatos TD,Tsimihodimos V,Elisaf MS.Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2(SGLT2)inhibitors[J].Expert Opin Pharmacother,2016,17(12):1581-1583.DOI:10.1080/14656566.2016.1201073.
[8] Rosenstock J,Seman LJ,Jelaska A,et al.Efficacy and safety of empagliflozin,a sodium glucose cotransporter 2(SGLT2)inhibitor,as add-on to metformin in type 2 diabetes with mild hyperglycaemia[J].Diabetes Obes Metab,2013,15(12):1154-1160.DOI:10.1111/dom.12185.
[9] Häring HU,Merker L,Seewaldt-Becker E,et al.Empagliflozin as add-on to metformin in patients with type 2 diabetes:a 24-week,randomized,double-blind,placebo-controlled trial[J].Diabetes Care,2014,37(6):1650-1659.DOI:10.2337/dc13-2105.
[10] Merker L,Haring HU,Christiansen AV,et al.Empagliflozin as add-on to metformin in people with type 2 diabetes[J].Diabetic Medicine,2015,32(12):1555-1567.DOI:10.1111/dme.12814.
[11] DeFronzo RA,Lewin A,Patel S,et al.Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin[J].Diabetes Care,2015,38(3):384-393.DOI:10.2337/dc14-2364.
[12] Ferrannini E,Berk A,Hantel S,et al.Long-term safety and efficacy of empagliflozin,sitagliptin,and metformin:an active-controlled,parallel-group,randomized,78-week open-label extension study in patients with type 2 diabetes[J].Diabetes Care,2013,36(12):4015-4021.DOI:10.2337/dc13-0663.
[13] Ridderstrale M,Andersen KR,Zeller C,et al.Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes:a 104-week randomised,active-controlled,double-blind,phase 3 trial[J].Lancet Diabetes Endocrinol,2014,2(9):691-700.DOI:10.1016/S2213-8587(14)70120-2.
[14] Kedia R,Kulkarni S,Ross M,et al.Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes:a systematic review[J].Patient Prefer Adherence,2016,10:1999-2006.DOI:10.2147/PPA.S85748.
[15] Rojas C,Link J,Meinicke T,et al.Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects[J].Int J Clin Pharmacol Ther,2016,54(4):282-292.DOI:10.5414/CP202425.
[16] Hadjadj S,Rosenstock J,Meinicke T,et al.Initial combination of empagliflozin and metformin in patients with type 2 diabetes[J].Diabetes Care,2016,39(10):1718-1728.DOI:10.2337/dc16-0522.
[17] Lau DT,Nau DP.Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes[J].Diabetes Care,2004,27(9):2149-2153.DOI:10.2337/diacare.27.9.2149.
[18] Balkrishnan R,Rajagopalan R,Camacho FT,et al.Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus:a longitudinal cohort study[J].Clin Ther,2003,25(11):2958-2971.DOI:10.1016/s0149-2918(03)80347-8.
[19] Lokhandwala T,Smith N,Sternhufvud C,et al.A retrospective study of persistence,adherence,and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs[J].J Med Econ,2016,19(3):203-212.DOI:10.3111/13696998.2015.1109518.
[20] Dekkers CCJ,Gansevoort RT,Heerspink HJL.New diabetes therapies and diabetic kidney disease progression:the role of SGLT-2 inhibitors[J].Curr Diab Rep,2018,18(5):27.DOI:10.1007/s11892-018-0992-6.
[21] Kuchay MS,Krishan S,Mishra SK,et al.Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease:a randomized controlled trial(E-LIFT Trial)[J].Diabetes Care,2018,41(8):1801-1808.DOI:10.2337/dc18-0165.
[22] Tikkanen I,Narko K,Zeller C,et al.Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension[J].Diabetes Care,2015,38(3):420-428.DOI:10.2337/dc14-1096.
[23] Zinman B,Wanner C,Lachin JM,et al.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J].N Engl J Med,2015,373(22):2117-2128.DOI:10.1056/NEJMoa1504720.
[24] Gillani SW,Ghayedi N,Roosta P,et al.Effect of metformin on lipid profiles of type 2 diabetes mellitus:a meta-analysis of randomized controlled trials[J].J Pharm Bioallied Sci,2021,13(1):76-82.DOI:10.4103/jpbs.JPBS_370_20.
[25] Weng S,Luo Y,Zhang Z,et al.Effects of metformin on blood lipid profiles in nondiabetic adults:a meta-analysis of randomized controlled trials[J].Endocrine,2020,67(2):305-317.DOI:10.1007/s12020-020-02190-y.
[26] Zhao D,Liu H,Dong P.Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus:a systematic review and meta-analysis[J].J Hum Hypertens,2019,33(4):327-339.DOI:10.1038/s41371-018-0134-2.
[27] 曹雯,孙洪平,范尧夫,等.二甲双胍对尿酸代谢的影响及其机制[J].中国老年学杂志,2017,37(13):3376-3378.DOI:10.3969/j.issn.1005-9202.2017.13.116
[28] Inzucchi SE,Fitchett D,Jurisˇic'-Erzˇen D,et al.Are the cardiovascular and kidney benefitsof empagliflozin influenced by baseline glucose-lowering therapy[J].Diabetes Obes Metab,2020,22(4):631-639.DOI:10.1111/dom.13938.
[29] Ji Q,Ji L,Mu Y,et al.Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index:A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia[J].Diabetes Obes Metab,2021,23(8):1886-1891.DOI:10.1111/dom. 14415
[30] Patorno E,Pawar A,Franklin JM,et al.Empagliflozin selected cardiovascular and safety outcomes in routine care:First results from the empagliflozin comparative effectiveness and safety(EMPRISE)study[C].Metabolism,2020,104.DOI:10.1016/j.metabol.2019.12.072.
[31] Einarson TR,Acs A,Ludwig C,et al.Prevalence of cardiovascular disease in type 2 diabetes:a systematic literature review of scientific evidence from across the world in 2007-2017[J].Cardiovasc Diabetol,2018,17(1):83.DOI:10.1186/s12933-018-0728-6.
[32] Packer M,Anker SD,Butler J,et al.Cardiovascular and renal outcomes with empagliflozin in heart failure[J].N Engl J Med,2020,383(15):1413-1424.DOI:10.1056/NEJMoa2022190.
[33] Anker SD,Butler J,Filippatos G,et al.Empagliflozin in heart failure with a preserved ejection fraction[J].N Engl J Med,2021,385(16):1451-1461.DOI:10.1056/NEJMoa2107038
[34] Salah HM,Al'Aref SJ,Khan MS,et al.Effect of sodium-glucose cotransporter 2 inhibitorson cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials[J].Am Heart J,2021,232:10-22.DOI:10.1016/j.ahj.2020.10.064.
[35] Cao H,Liu Y,Tian Z,et al.Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4:a systematic review and meta-analysis of randomized clinical trials[J]. Diabetes Res Clin Pract,2021,180:109033.DOI:10.1016/j.diabres.2021.109033.
[36] Seino Y,Kim DJ,Yabe D,et al.Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia:results from the EMPRISE East Asia study[J].Endocrinol Diabetes Metab,2020,4(1):e00183.DOI:10.1002/edm2.183.
[37] Holman RR,Paul SK,Bethel MA,et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15):1577-1589.DOI:10.1056/NEJMoa0806470
[38] Hong J,Zhang Y,Lai S,et al.Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease[J].Diabetes Care,2013,36(5):1304-1311.DOI:10.2337/dc12-0719.
[39] Eurich DT,Weir DL,Majumdar SR,et al.Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure:systematic review of observational studies involving 34,000 patients[J].Circ Heart Fail,2013,6(3):395-402.DOI:10.1161/CIRCHEARTFAILURE.112.000162.
[40] Han Y,Xie H,Liu Y,et al.Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases:a systematic review and an updated meta-analysis[J].Cardiovasc Diabetol,2019,18(1):96.DOI:10.1186/s12933-019-0900-7.
[41] Zhang K,Yang W,Dai H,et al.Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus:results from meta-analysis[J].Diabetes Res Clin Pract,2020,160:108001.DOI:10.1016/j.diabres.2020.108001.
[42] Schernthaner G,Brand K,Bailey CJ.Metformin and the heart:Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure[J].Metabolism,2022,130:155160.DOI:10.1016/j.metabol.2022.155160.
[43] 纪立农,郭立新,郭晓蕙,等.钠-葡萄糖共转运蛋白2(SGLT2)抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志,2016,24(10):865-870.DOI:10.3969/j.issn.1006-6187.2016.10.01.
[44] Dashora U,Gregory R,Winocour P,et al.Association of British Clinical Diabetologists(ABCD)and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes(January 2021)[J].Clin Med(Lond),2021,21(3):204-210.DOI:10.7861/clinmed.2021-0045.

相似文献/References:

[1]孟旭英,范振迁,郭剑超.利拉鲁肽与格列美脲治疗2型糖尿病的系统评价[J].国际内分泌代谢杂志,2016,36(06):380.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
　Meng Xuying,Fan Zhenqian,Guo Jianchao..Effects of liraglutide versus glimepiride for type 2 diabetes mellitus: a systematic review[J].International Journal of Endocrinology and Metabolism,2016,36(05):380.[doi:10.3760/cma.j.issn.1673-4157.2016.06.05]
[2]韩秀丹 朱凌燕 徐积兄.二甲双胍对糖尿病视网膜病变的作用及机制[J].国际内分泌代谢杂志,2019,39(01):53.[doi:10.3760/cma.j.issn.1673-4157.2019.01.013]
　Han Xiudan,Zhu Lingyan,Xu Jixiong.Effects of metformin on diabetic retinopathy and its mechanism[J].International Journal of Endocrinology and Metabolism,2019,39(05):53.[doi:10.3760/cma.j.issn.1673-4157.2019.01.013]
[3]谢叶红 黄明春.二甲双胍降低T2DM血清维生素B12的研究进展[J].国际内分泌代谢杂志,2020,40(01):35.[doi:10.3760/cma.j.issn.1673-4157.2020.01.008]
　Xie Yehong,Huang Mingchun.Progress of metformin in reducing serum vitamin B12 in T2DM[J].International Journal of Endocrinology and Metabolism,2020,40(05):35.[doi:10.3760/cma.j.issn.1673-4157.2020.01.008]
[4]《钠-葡萄糖共转运蛋白抑制剂联合二甲双胍治疗型糖尿病专家共识》专家组.钠-葡萄糖共转运蛋白2抑制剂联合二甲双胍治疗2型糖尿病专家共识[J].国际内分泌代谢杂志,2023,43(05):437.[doi:10.3760/cma.j.cn121383-20230725-07036]
　Expert Group for Expert Consensus on Sodium-Glucose Cotransporter- Inhibitors with Metformin in Patients with Type Diabetes Mellitus.Expert consensus on sodium-glucose cotransporter-2 inhibitors with metformin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2023,43(05):437.[doi:10.3760/cma.j.cn121383-20230725-07036]

备注/Memo

备注/Memo:
通信作者:母义明,解放军总医院第一医学中心内分泌科,北京 100853,Email: muyiming@301hospital.com.cn; 朱大龙,南京大学医学院附属鼓楼医院内分泌科 210008,Email: zhudalong@nju.edu.cn
更新日期/Last Update: 2022-09-10